A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical trial NCT06711900 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06711900
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2024-10-30
Primary completion: 2026-12-01
Enrollment: 432

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.